Hyperimmune products in the prevention and therapy of infectious disease: A report of a hyperimmune products expert advisory panel

BioDrugs

Volumn 14, Issue 3, 2000, Pages 147-158

  Deresinski, S C ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; BACTERIAL ANTIGEN; BOTULINUM ANTISERUM; CYTOKINE ANTIBODY; HEPATITIS A ANTIBODY; HERPES ZOSTER IMMUNOGLOBULIN; HYPERIMMUNE GLOBULIN; LAMIVUDINE; LOBUCAVIR; MEASLES ANTIBODY; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; PALIVIZUMAB; POLYCLONAL ANTIBODY; POLYSACCHARIDE; RABIES IMMUNOGLOBULIN; STAPHYLOCOCCUS VACCINE; SUPERANTIGEN; TETANUS ANTIBODY;

CAMPYLOBACTER JEJUNI; CLINICAL TRIAL; DRUG CONTROL; DRUG DISTRIBUTION; DRUG EFFICACY; EPSTEIN BARR VIRUS; GASTROINTESTINAL INFECTION; HALF LIFE TIME; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INFECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEWBORN SEPSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; THERAPY;

EID: 0033782581     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014030-00002     Document Type: Review

References (63)

1. Measles, mumps and rubella - Vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2. A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices
3. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
4. Diphtheria, tetanus and pertussis: Recommendations for vaccine use and other preventative measures. Recommendations of the Immunization Practices Advisory Committee (ACIP)
5. Antitoxin levels in botulism patients treated with trivalent equine botulism anti-toxin to toxin types A, B, and E
6. Human rabies prevention - United States 1999. Recommendations of the Advisory Committee on Immunization Practices
7. Treatment and prevention of respiratory syncytial virus infection
8. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group
9. Recommendation of the Immunization Practices Advisory Committee (ACIP) postexposure prophylaxis of hepatitis B
10. Liver transplantation in HBs antigen (HbsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization
11. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
12. The post-antibiotic era beckons
13. Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus
14. Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection
15. Potential for vaccination against infections caused by Staphylococcus aureus
16. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections
17. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients
18. Vancomycin-resistant enterococci: The clinical effect of a common nosocomial pathogen
19. Isolation and chemical characterization of a capsular polysaccharide antigen shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium
20. O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections
21. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas 0-polysaccharide conjugate vaccine administered to victims of acute trauma
22. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group
23. Evolution of maternofetal transport of immunoglobulins during human pregnancy
24. Maternal-fetal transport of immunoglobulin G and its subclasses during the third trimester of human pregnancy
25. A randomized, double-blind, placebo-controlled investigation of the safety of intravenous immune globulin administration to preterm neonates
26. Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates
27. The use of intravenous gammaglobulin for prevention of sepsis in pre-term infants. A controlled clinical trial
28. Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates
29. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network
30. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: Report of a pilot study
31. Intravenous immune globulin for the prevention of nosocomial infection in low-birthweight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates
32. Intravenous gamma globulin in the prophylaxis of late sepsis in very-low-birth-weight infants: Preliminary results of a randomized, double-blind, placebo-controlled trial
33. Liver transplantation in the United States from 1987-1998: Updated results from the Pitt-UNOS Liver Transplant Registry
34. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database
35. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation
36. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression
37. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
38. End-stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B
39. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B
40. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
41. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
42. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization
43. At least three epitopes are recognised by the human repertoire in the hepatitis B virus group a antigen inducing protection: Possible consequences for seroprevention and serodiagnosis
44. Characterization of the reactivity pattern of murine monoclonal antibodies against wildtype hepatitis B surface antigen to G145R and other naturally occurring 'a' loop escape mutations
45. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: An experimental study in the chimpanzee
46. Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation electrofusion
47. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation
48. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial
49. Binding of hepatitis C virus to CD81
50. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypevariable region 1 of the envelope 2 protein
51. Gamma-globulin modulates growth of EBV-derived B-cell tumors in SCID mice reconstituted with human lymphocytes
52. Preventive effect of IgG from EBV-seropositive donors on the development of human lymphoproliferative disease in SCID mice
53. Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients
54. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
55. Campylobacter enteritis in normal and immunodeficient children
56. An unusual case of refractory Campylobacter jejuni infection in a patient with X-linked agammaglobulinemia: Successful combined therapy with maternal plasma and ciprofloxacin
57. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum
58. Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations
59. Use of immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with persistent Campylobacter jejuni infection
60. Respiratory syncytial virus infections and intravenous gamma-globulins
61. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: Safety and pharmacokinetics. The RSVIG Study Group
62. Respiratory syncytial virus (RSV) infection in preterm infants and the protective efforts of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group
63. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab (American Academy of Pediatrics)